Please use this identifier to cite or link to this item: http://hdl.handle.net/1893/24110
Appears in Collections:Aquaculture Journal Articles
Peer Review Status: Refereed
Title: Urinary proteomics in obstructive sleep apnoea and obesity
Author(s): Seetho, Ian W
Siwy, Justyna
Albalat, Amaya
Mullen, William
Mischak, Harald
Parker, Robert J
Craig, Sonya
Duffy, Nick
Hardy, Kevin J
Burniston, Jatin G
Wilding, John P H
Contact Email: amaya.albalat@stir.ac.uk
Keywords: Obesity
obstructive sleep apnoea
urinary proteomics
Issue Date: Nov-2014
Date Deposited: 26-Aug-2016
Citation: Seetho IW, Siwy J, Albalat A, Mullen W, Mischak H, Parker RJ, Craig S, Duffy N, Hardy KJ, Burniston JG & Wilding JPH (2014) Urinary proteomics in obstructive sleep apnoea and obesity. European Journal of Clinical Investigation, 44 (11), pp. 1104-1115. https://doi.org/10.1111/eci.12346
Abstract: Background:  Obstructive sleep apnoea (OSA) is a common complication of obesity and can have a substantial negative impact on a patient's quality of life and risk of cardiovascular disease. The aim of this case-control study was to undertake discovery profiling of urinary peptides using capillary electrophoresis-mass spectrometry (CE-MS) in obese subjects with and without OSA, without a history of coronary artery disease.  Materials and methods:  Urinary samples were analysed by CE-MS. Body composition and blood pressure measurements were recorded. Overnight polysomnography was conducted to confirm or refute OSA. OSA patients were naïve to continuous positive airway pressure treatment.  Results:  Sixty-one subjects with OSA (age 47 ± 9 years, BMI 43 ± 8 kg/m2) and 31 controls (age 49 ± 10 years, BMI 40 ± 5 kg/m2) were studied; P = ns for age and BMI. Apnoea-hypopnoea Index was higher in patients with OSA (24 ± 18·6) than controls without OSA (non-OSA) (2·6 ± 1·1; P < 0·0001). Metabolic syndrome was present in 35 (57%) of those with OSA compared with 4 (13%) of controls (P < 0·0001). Twenty-four polypeptides were candidates for differential distribution (P < 0·01), although these differences did not reach significance after multiple testing. Sequences were determined for eight peptides demonstrating origins from collagens and fibrinogen alpha.  Conclusions:  In this study, we report for the first time, urinary proteomic profile analyses using CE-MS in OSA and non-OSA obese groups. The differences in urinary proteomic profiles prior to adjustment for multiple testing, with increased metabolic syndrome in obese OSA subjects, suggest that there may be a role for CE-MS in characterising urinary profiles in severely obese populations with OSA. © 2014 Stichting European Society for Clinical Investigation Journal Foundation.
DOI Link: 10.1111/eci.12346
Rights: The publisher does not allow this work to be made publicly available in this Repository. Please use the Request a Copy feature at the foot of the Repository record to request a copy directly from the author. You can only request a copy if you wish to use this work for your own research or private study.
Licence URL(s): http://www.rioxx.net/licenses/under-embargo-all-rights-reserved

Files in This Item:
File Description SizeFormat 
Seetho_et_al-2014-European_Journal_of_Clinical_Investigation.pdfFulltext - Published Version369.06 kBAdobe PDFUnder Embargo until 2999-12-30    Request a copy

Note: If any of the files in this item are currently embargoed, you can request a copy directly from the author by clicking the padlock icon above. However, this facility is dependent on the depositor still being contactable at their original email address.



This item is protected by original copyright



Items in the Repository are protected by copyright, with all rights reserved, unless otherwise indicated.

The metadata of the records in the Repository are available under the CC0 public domain dedication: No Rights Reserved https://creativecommons.org/publicdomain/zero/1.0/

If you believe that any material held in STORRE infringes copyright, please contact library@stir.ac.uk providing details and we will remove the Work from public display in STORRE and investigate your claim.